Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-02-08FDA Approved: LENALIDOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical Industries' Lenalidomide Original Application, granting a generic lenalidomide product for multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL [Phase 1, Phase 2]
Dose-escalation early-stage trial assessing safety of PBCAR20A in relapsed/refractory Non-Hodgkin's Lymphoma and relapsed/refractory Chronic…
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention [Phase 3]
Phase 3 trial comparing Tacrolimus plus mini-methotrexate versus Tacrolimus plus methotrexate for graft-versus-host disease prevention has c…
-
CLINICAL_TRIALS trial_result · 2023-01-23Clinical Trial Update: Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis [Phase 2]
Phase 2 trial of adoptive immunotherapy in relapsed hematological malignancies with early GVHD prophylaxis has completed enrollment and post…
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating ibrutinib in patients with refractory or relapsed lymphoma after donor stem cell transplant completed; results post…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-01-19FDA Approved: BRUKINSA — Supplemental Application (BeOne Medicines USA, Inc.)
FDA approved a supplemental application for BRUKINSA (zanubrutinib) submitted by BeOne Medicines USA, Inc.
-
CLINICAL_TRIALS trial_result · 2023-01-17Clinical Trial Update: Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL [Phase 2]
Phase 2 trial evaluating the combination of ibrutinib, venetoclax, and obinutuzumab in patients with chronic lymphocytic leukemia (CLL) has …
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL [Phase 3]
Phase 3 trial evaluating acalabrutinib with obinutuzumab and chlorambucil for treatment-naïve chronic lymphocytic leukemia; results have bee…
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL [Phase 3]
Phase 3 trial update on acalabrutinib with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.
-
CLINICAL_TRIALS trial_result · 2022-12-19Clinical Trial Update: A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy [Phase 2]
Phase 2 open-label study of ABT-199 (venetoclax) in chronic lymphocytic leukemia patients relapsed/refractory after BCR signaling pathway in…
-
FDA approval · 2022-12-07FDA Approved: VIVIMUSTA — Original Application (Azurity Pharmaceuticals, Inc.)
FDA approved VIVIMUSTA (bendamustine hydrochloride) from Azurity Pharmaceuticals under Original Application NDA212209.
-
FDA approval · 2022-12-07FDA Approved: BENDAMUSTINE HYDROCHLORIDE — Original Application (Apotex Corp)
FDA approved bendamustine hydrochloride via Apotex Corp's original application, indicating the approval of a Bendamustine HCl product.
-
CLINICAL_TRIALS research · 2022-12-01Clinical Trial Update: Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 1, Phase 2]
A completed Phase 1/Phase 2 clinical trial evaluating pyrimethamine for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma; re…
-
CLINICAL_TRIALS trial_result · 2022-11-28Clinical Trial Update: iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL [Phase 2]
Phase 2 clinical trial update for iVAC-CLL01, a patient-individualized peptide vaccination after first-line therapy in chronic lymphocytic l…
-
CLINICAL_TRIALS trial_result · 2022-11-21Clinical Trial Update: Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update on ublituximab for relapsed or refractory B-cell non-Hodgkin lymphoma completed phases 1 and 2.
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy [Phase 3]
A Phase 3 study in previously untreated chronic lymphocytic leukemia (excluding 17p deletion) evaluating debulking regimens before starting …
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies [Phase 2]
Phase 2 clinical trial update on shorter course tacrolimus after non-myeloablative conditioning with related donor PBSCT and high-dose postt…
-
CLINICAL_TRIALS trial_result · 2022-10-24Clinical Trial Update: Ublituximab + Ibrutinib in Select B-cell Malignancies [Phase 1, Phase 2]
A phase 1/2 trial evaluating ublituximab in combination with ibrutinib for select B-cell malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2022-10-10Clinical Trial Update: Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide [Phase 2]
Phase II trial protocol in chronic lymphocytic leukemia evaluates the FCR regimen (fludarabine, cyclophosphamide, rituximab) with lenalidomi…
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 clinical trial of lenalidomide and obinutuzumab in patients with recurrent or refractory chronic lymphocytic leukemia or small lymph…
-
CLINICAL_TRIALS trial_result · 2022-09-19Clinical Trial Update: Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma [Phase 2]
Phase 2 trial evaluating acalabrutinib in combination with the R-ICE chemotherapy regimen for relapsed or refractory lymphoma; the study was…
-
CLINICAL_TRIALS trial_result · 2022-09-16Clinical Trial Update: Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab [Phase 2]
Phase 2 trial update for GELLC-7 protocol evaluating iBrutinib followed by consolidation with ofatumumab in Chronic Lymphocytic Leukemia.
-
CLINICAL_TRIALS trial_result · 2022-09-10Clinical Trial Update: ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia [Phase 1, Phase 2]
ACP-196 (acalabrutinib), a BTK inhibitor, is being studied in Phase 1/2 trials for chronic lymphocytic leukemia, Richter's syndrome, small l…
-
FDA approval · 2022-09-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
The FDA approved Exelan Pharmaceuticals Inc.'s original application for lenalidomide, granting approval of a generic version of the cancer d…
-
CLINICAL_TRIALS trial_result · 2022-08-31Clinical Trial Update: Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies [Phase 1]
Phase 1 trial update of a genetically modified T-cell therapy targeting ROR1 in advanced malignancies, with terminated status and posted res…